Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
J BUON. 2020 May-Jun;25(3):1619-1624.
To explore the associations between the expressions of micro ribonucleic acid (miR)-135 and miR-92a and the pathogenesis of prostate cancer, as well as their clinical significance.
A total of 40 prostate cancer patients were studied. The associations of expressions of miR-135 and miR-92a with the pathological Gleason score and expression of prostate specific antigen (PSA) were assessed, the sensitivity and specificity of miR-135 and miR-92a in the diagnosis of prostate cancer were compared, and the associations between the expressions of miR-135 and miR-92a and the prognosis of prostate cancer patients were evaluated.
In patients with pathological Gleason score ≥8 points the expression level of miR-135 was significantly lower (p<0.05), while that of miR-92a was significantly higher than those in patients with pathological Gleason score <8 points (p<0.05). In patients with PSA expression >10 ng/mL the expression level of miR-135 was obviously lower (p<0.05), while that of miR-92a was obviously higher than those in patients with PSA expression ≤10 ng/mL (p<0.05). The expression of miR-135 was negatively correlated with the pathological Gleason score and PSA expression (p<0.05), while the expression of miR-92a was positively correlated with the pathological Gleason score and PSA expression (p<0.05). The sensitivity and specificity of miR-135 and miR-92a in the diagnosis were above 80% and about 70%, respectively. In miR-135-positive patients, the mean survival time was longer (p<0.05) and the 2-year survival rate was higher than those in miR-135-negative patients (p<0.05). In miR-92a-positive patients, the mean survival time was shorter (p<0.05) and the 2-year survival rate was lower than those in miR-92a-negative patients (p<0.05).
The expressions of miR-135 and miR-92a are of certain value in screening prostate cancer. The prognosis and survival of patients are positively correlated with the miR-135 expression and negatively correlated with the miR-92a expression.
探讨微小 RNA（miR）-135 和 miR-92a 的表达与前列腺癌发病机制的关系及其临床意义。
研究了 40 例前列腺癌患者。评估了 miR-135 和 miR-92a 的表达与前列腺特异性抗原（PSA）表达的病理 Gleason 评分的关系，比较了 miR-135 和 miR-92a 对前列腺癌的诊断的敏感性和特异性，并评估了 miR-135 和 miR-92a 的表达与前列腺癌患者预后的关系。
病理 Gleason 评分≥8 分患者 miR-135 表达水平明显降低（p<0.05），而 miR-92a 表达水平明显升高（p<0.05）。PSA 表达>10ng/ml 的患者 miR-135 表达水平明显降低（p<0.05），而 miR-92a 表达水平明显升高（p<0.05）。miR-135 的表达与病理 Gleason 评分和 PSA 表达呈负相关（p<0.05），而 miR-92a 的表达与病理 Gleason 评分和 PSA 表达呈正相关（p<0.05）。miR-135 和 miR-92a 诊断的敏感性和特异性均在 80%以上，约为 70%。miR-135 阳性患者的平均生存时间较长（p<0.05），2 年生存率高于 miR-135 阴性患者（p<0.05）。miR-92a 阳性患者的平均生存时间较短（p<0.05），2 年生存率低于 miR-92a 阴性患者（p<0.05）。
miR-135 和 miR-92a 的表达在筛选前列腺癌方面具有一定价值。患者的预后和生存与 miR-135 的表达呈正相关，与 miR-92a 的表达呈负相关。
